News

Public · Published

Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases

Cerenome, Inc. announced that interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ will be presented in a poster at the 2026 SNO Annual Meeting in Philadelphia, November 12–15, covering the first ten patients.

Published:

Updated:

What happened

Cerenome, Inc. announced that interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ will be presented in a poster at the 2026 SNO Annual Meeting in Philadelphia, November 12–15, covering the first ten patients.

Confirmed

Global impact / market context

The data cover safety, dosing, and tumor-cell measures in leptomeningeal metastases, a fatal condition with no approved treatments. Positive results could support an FDA-aligned Phase 2 dose randomization study in 2027, a key step toward potential accelerated approval and eventual revenue.

Analyst inference

Cerenome is a CNS oncology company combining diagnostics, therapeutics, and artificial intelligence. For investors, the interim readout is a near-term catalyst that could shape expectations for the 2027 Phase 2 plan and the company's path to a first approved product.

Analyst inference

What to watch

  1. The poster will report interim safety, dosimetry, CSF tumor cell enumeration (biomarker), and individual treatment course data on the first ten patients from the multidose ReSPECT-LMM study. Confirmed
  2. Cerenome aims to advance into an FDA-aligned Phase 2 dose randomization study in 2027, which would support potential accelerated approval or a follow-on registrational Phase 3 study. Proposed
  3. Watch whether the interim safety and biomarker results support repeated REYOBIQ dosing, since that readout could determine the timing and design of the planned 2027 Phase 2 study. Analyst inference

Evidence